COVID-19 Conversations Podcast: Participation in vaccine trial
UC dean for clinical research discusses his decision to participate, need for diversity in science
In November 2020, less than a year after SARS-CoV-2, the virus that causes COVID-19, was identified, the world received optimistic news about several vaccines that showed efficacy in fighting the disease. The world is now watching in excitement as the first COVID-19 vaccines are being administered in the United Kingdom and the U.S.
Researchers and scientists often receive accolades and awards when research is successful, but although the attention is well-deserved, the essential role of research participants, without whom none of the successes would be possible, should also be recognized and celebrated.
In the podcast series COVID-19 Conversations, hosts talk to three COVID-19 vaccine trial participants, including Brett Kissela, MD, senior associate dean for clinical research at the UC College of Medicine and chief of research services at UC Health.
In September, Kissela became a participant in the Moderna trial at the university.
In this podcast of the African Alliance, based in South Africa, Kissela discusses why he chose to particpate, his experiences, hopes and fears as well as what he wants others, globally, to know about the research process.
Featured photo of Brett Kissela participating in the Moderna vaccine trial by Colleen Kelley.
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up on all UC's COVID-19 stories, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
Related Stories
WLWT: Tips to fight off bad allergy symptoms
April 18, 2024
The University of Cincinnati's Ahmad Sedaghat spoke with WLWT about how Cincinnati's geography tends to make allergy symptoms worse and tips to fight off those symptoms.
Medscape: Skin adverse events rare after immunotherapy to treat...
April 17, 2024
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found skin adverse events were rare following immunotherapy treatments for certain skin cancers.
UC researchers develop new CPAP device
April 17, 2024
Researchers at the University of Cincinnati are developing a VortexPAP machine that takes advantage of vortex airflow technology. A preliminary clinical study with current CPAP users demonstrated that the VortexPAP can deliver the pressure levels that are used in the subjects’ CPAP therapy, but the mask is more comfortable to wear. It has a minimalistic design that is less intrusive and barely touches the patient’s face.